September 30, 2024 11:03 AM EDT

Kezar halts mid-stage lupus study after four deaths

Max Bayer

Pharma Reporter

Kezar Life Sciences is suspending enrollment and dosing in a lupus trial after four patients died in the mid-stage study of its drug zetomipzomib, three …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kezar halts mid-stage lupus study after four deaths

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Updated: Roche buys Regor’s CDK inhibitors for $850M upfront amid push to develop 20 ‘transformative’ medicines

Poseida shares incremental Phase 1 update for Roche-partnered off-the-shelf CAR-T

Updated: Prime Medicine whittles down pipeline, signs gene editing deal with Bristol Myers

Lilly-partnered radiopharma startup Aktis Oncology raises $175M

For some multiple myeloma patients, Carvykti cut risk of death by 45%

3 Tiers for AAV Potency Assay Development Success

Kezar halts mid-stage lu­pus study af­ter four deaths

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Kezar halts mid-stage lupus study after four deaths